Stéphane Bancel, Moderna CEO (AP Photo/Markus Schreiber)
Updated: Moderna: Not enough flu cases in PhIII trial yet to tell efficacy
One of Moderna’s Phase III studies for its influenza vaccine candidate for adults, dubbed mRNA-1010, did not have enough cases at the time of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
